
1. j pediatr hematol oncol. 2014 mar;36(2):e69-74. doi:
10.1097/mph.0b013e31827e63a6.

rituximab lymphomatoid granulomatosis.

hernández-marqués c(1), lassaletta a, torrelo a, lópez-pino má, álvarez-coca j,
de prada i, hernández-martín á, madero l.

author information: 
(1)departments *pediatric hematology-oncology †dermatology ‡radiology
§paediatrics ∥pathology, hospital infantil universitario niño jesús, madrid,
spain.

background: lymphomatoid granulomatosis (lg) epstein-barr virus-associated,
multisystemic disease combines granulomatous inflammatory process with
lymphoproliferative potential. rare disorder variable clinical
presentation ranging indolent process aggressive b-cell lymphoma.
outcome unpredictable, standard treatment yet established. 
cases treated rituximab, anti-cd20 monoclonal antibody, been
reported variable results.
observation: report 2 children lg treated rituximab review
the literature. first patient good response second not.
conclusions: rituximab treatment option lg.

doi: 10.1097/mph.0b013e31827e63a6 
pmid: 23337550  [indexed medline]

